11.05.2021 • NewsBASFSandozNovartis

BASF Invests in Enzymes in Austria

BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau Campus in Austria. The German chemical giant said the agreement with the Swiss group – for which financial details were not disclosed – will enable it to develop a world-scale operation for bacterial enzymes and biotechnology products.

Start of production is planned for 2024, and BASF said it will explore the potential for a “deeper involvement” at the Austrian campus, which it noted has 75 years of biotechnology practice and corresponding infrastructure. “This investment is a clear sign of our commitment to the enzymes and biotechnology industry, said Michael De Marco, vice president Global Business Management Enzymes.

With the investment, Soeren Hildebrandt, senior vice president Home Care, I&I and Industrial Formulators Europe at BASF, said the Ludwigshafen-based group will be able to help customers to address key market needs such as cleaning products with superior sustainability profiles and new product formats, based on its innovative enzyme technology.

BASF will be the first external customer for the Life Science campus that the Swiss drugmaker is seeking to develop for the site in Austria’s Tyrol region, which in addition to accommodating Sandoz’ generics facilities is part of the Novartis anti-infectives platform. Specialized in biologics, from R&D to finished products, production there has a focus on antibiotics.

"Tyrol is a key location for our global production network. Our investments in Kundl and Schaftenau reinforce our commitment to the region," said Steffen Lang, head of Novartis Technical Operations and member of the Novartis executive committee. "With the further development into a Life Science Park and the settlement of BASF, an important player in the field of biotechnology, we are strengthening the competence and innovation capacity of the area."

Author: Dede Williams, Freelance Journalist

BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau...
BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau Campus in Austria. The German chemical giant said the investment, due to start up in 2024, could form the nucleus for world-scale production of bacterial enzymes and biotechnology products. (c) Novartis

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.